CF PHARMTECH (02652) announced that its leading inhaled nucleic acid drug development project has been selected for Jiangsu Province's 2025 Major Sci-Tech Program under the "Innovative Biopharmaceuticals" category. The project focuses on overcoming key challenges in pulmonary delivery of small interfering RNA (siRNA) drugs, aiming to advance translational research and preclinical development of inhaled nucleic acid drug candidates.

The initiative will support R&D for inhaled nucleic acid-based therapies targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. The scope covers optimization of delivery systems, pharmaceutical and process development, preclinical studies, and preparation for investigational new drug (IND) applications.

The company emphasized the strategic significance of this selection, which further validates the strength of its technology platform. Delivery technology remains a critical barrier in siRNA-based pulmonary therapies. CF PHARMTECH has independently developed a high-efficiency lung-targeted delivery system, with related drug candidates demonstrating promising therapeutic potential in preclinical studies.

This recognition reflects strong endorsement by regulatory authorities and expert reviewers of the company's collaborative R&D capabilities in cutting-edge delivery technologies. CF PHARMTECH remains committed to technological innovation to deliver higher-value therapies for patients while creating sustainable long-term returns for shareholders.